Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.67 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.44 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587 | 0.88 | LPAR1 (0.53) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL18597681 | 0.85 | LPAR1 (0.52) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL1345 | 0.82 | LPAR1 (0.53) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL11895595 | 0.82 | LPAR1 (0.46) | LPAR1LPAR3LPAR2PTGDR2ABCC4 | |
| SCHEMBL5585 | 0.82 | LPAR1 (0.47) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL1286658 | 0.81 | LPAR1 (0.68) | LPAR1LPAR3LPAR2PTGDR2ABCC4 | |
| SCHEMBL2288090 | 0.80 | LPAR1 (1.00) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL2296696 | 0.80 | LPAR1 (1.00) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL13283727 | 0.80 | LPAR1 (0.79) | LPAR1LPAR3LPAR2ABCC4ABCC3 | |
| SCHEMBL2288084 | 0.80 | LPAR1 (1.00) | LPAR1LPAR3LPAR2ABCC4ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| WO-2011159550-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND USES THEREOF | AMIDRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-8048902-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2358688-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC., (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.